Caribou Biosciences Inc
Company Profile
Business description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Contact
2929 7th Street
Suite 105
BerkeleyCA94710
USAT: +1 510 982-6030
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
147
Stocks News & Analysis
stocks
Amazon earnings: Guidance for $200 billion in capital expenditure in 2026 overshadows good results
stocks
Apple earnings: Impressive Q4 lifts stock, but is it a long-term growth play?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 72.70 | 0.80% |
| CAC 40 | 8,273.84 | 11.68 | 0.14% |
| DAX 40 | 24,721.46 | 230.40 | 0.94% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,369.75 | 60.53 | 0.59% |
| HKSE | 26,919.58 | 359.63 | 1.35% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 56,498.53 | 2,244.85 | 4.14% |
| NZX 50 Index | 13,446.37 | 2.35 | 0.02% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,877.90 | 67.00 | 0.76% |
| SSE Composite Index | 4,110.26 | 44.68 | 1.10% |